Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

PMID:
29142089
2.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, PĂ©rez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.

3.

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391.

4.

Amantadine's role in the treatment of levodopa-induced dyskinesia.

Rodnitzky RL, Narayanan NS.

Neurology. 2014 Jan 28;82(4):288-9. doi: 10.1212/WNL.0000000000000068. Epub 2013 Dec 26. No abstract available.

PMID:
24371305
5.

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators.

JAMA Neurol. 2013 Nov;70(11):1382-8. doi: 10.1001/jamaneurol.2013.3487.

6.

Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

Narayanan NS, Rodnitzky RL, Uc EY.

Rev Neurosci. 2013;24(3):267-78. doi: 10.1515/revneuro-2013-0004. Review.

8.

Upcoming treatments in Parkinson's disease, including gene therapy.

Rodnitzky RL.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S37-40. doi: 10.1016/S1353-8020(11)70014-1. Review.

PMID:
22166449
9.

Secondary dystonia in a botulinum toxin clinic: clinical characteristics, neuroanatomical substrate and comparison with idiopathic dystonia.

Strader S, Rodnitzky RL, Gonzalez-Alegre P.

Parkinsonism Relat Disord. 2011 Dec;17(10):749-52. doi: 10.1016/j.parkreldis.2011.07.013. Epub 2011 Aug 17.

PMID:
21852177
10.

Cerebellar pathology and essential tremor: did Dr. Purkinje leave any fingerprints?

Rodnitzky RL.

Parkinsonism Relat Disord. 2011 Jul;17(6):405. doi: 10.1016/j.parkreldis.2011.05.006. Epub 2011 May 20. No abstract available.

PMID:
21600831
11.

Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Thomsen TR, Rodnitzky RL.

CNS Drugs. 2010 Jun;24(6):467-77. doi: 10.2165/11533130-000000000-00000. Review.

PMID:
20443646
12.

Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants.

Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study Group.

Neurology. 2009 Aug 4;73(5):385-92. doi: 10.1212/WNL.0b013e3181b04aa2.

13.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators.

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
14.

Impaired Curve Negotiation in Drivers with Parkinson's Disease.

Uc EY, Rizzo M, Dastrup E, Sparks J, Anderson SW, Rodnitzky RL, Dawson JD.

Turk Noroloji Dergisi. 2009 Jan 19;15(1):10-18. No abstract available.

15.

From essential tremor to Klinefelter through Fragile X, an unexpected journey.

Harlow TL, Rodnitzky RL, Gonzalez-Alegre P.

Mov Disord. 2008 Jul 15;23(9):1328-9. doi: 10.1002/mds.22033. No abstract available.

PMID:
18464279
16.

Impaired navigation in drivers with Parkinson's disease.

Uc EY, Rizzo M, Anderson SW, Sparks JD, Rodnitzky RL, Dawson JD.

Brain. 2007 Sep;130(Pt 9):2433-40. Epub 2007 Aug 8.

PMID:
17686809
17.

Driving with distraction in Parkinson disease.

Uc EY, Rizzo M, Anderson SW, Sparks JD, Rodnitzky RL, Dawson JD.

Neurology. 2006 Nov 28;67(10):1774-80.

PMID:
17130409
18.

Impaired visual search in drivers with Parkinson's disease.

Uc EY, Rizzo M, Anderson SW, Sparks J, Rodnitzky RL, Dawson JD.

Ann Neurol. 2006 Oct;60(4):407-13.

PMID:
16969860
19.

Isolated high-frequency jaw tremor relieved by botulinum toxin injections.

Gonzalez-Alegre P, Kelkar P, Rodnitzky RL.

Mov Disord. 2006 Jul;21(7):1049-50.

PMID:
16602105
20.

Predictors of weight loss in Parkinson's disease.

Uc EY, Struck LK, Rodnitzky RL, Zimmerman B, Dobson J, Evans WJ.

Mov Disord. 2006 Jul;21(7):930-6.

PMID:
16534756

Supplemental Content

Loading ...
Support Center